Boston Scientific Corporation (FRA:BSX)
Market Cap | 132.63B |
Revenue (ttm) | 16.24B |
Net Income (ttm) | 1.88B |
Shares Out | n/a |
EPS (ttm) | 1.27 |
PE Ratio | 70.55 |
Forward PE | 34.37 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2 |
Average Volume | 399 |
Open | 90.00 |
Previous Close | 89.00 |
Day's Range | 90.00 - 90.40 |
52-Week Range | 65.50 - 104.00 |
Beta | n/a |
RSI | 45.16 |
Earnings Date | Jul 23, 2025 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews
Is Boston Scientific Gaining or Losing Market Support?
Boston Scientific's (NYSE: BSX) short percent of float has risen 6.6% since its last report. The company recently reported that it has 16.75 million shares sold short , which is 1.13% of all regular ...

P/E Ratio Insights for Boston Scientific
In the current market session, Boston Scientific Inc. (NYSE: BSX) stock price is at $104.20, after a 0.29% drop. However, over the past month, the company's stock increased by 0.10% , and in the past...
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire
Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Boston Scientific Corporation (NYSE: BSX) is pulling the plug on its ACURATE neo2 and Prime aortic valve systems . What Happened : The medical technology giant halted global sales and abandoned regul...

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Boston Scientific Corporation BSX is pulling the plug on its ACURATE neo2 and Prime aortic valve systems.
Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott
Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.
Edwards Lifesciences, Medtronic gain as Boston Scientific pulls aortic valve systems

Boston Scientific to not seek US approval for heart device amid regulatory challenges
Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

$1000 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.95% on an annualized basis producing an average annual return of 21.03%. Currently, Boston Scientific has a marke...
Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)
Boston Scientific Stock Flirts With A Buy Point, Once Again
Boston Scientific stock is wavering around the buy point of a double-bottom base. The company recently raised its 2025 earnings outlook.

$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a marke...

Boston Scientific announces upcoming investor conference schedule
MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results
Boston Scientific Corporation (NYSE: BSX) posted better-than-expected earnings for the first quarter on Wednesday . The company reported first-quarter 2025 revenues of $4.66 billion, beating the cons...

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results
Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.
IBD Stock Of The Day, Boston Scientific, A 'Top Decile' Player, Is Eyeing Two Entries
Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.
Boston scientific raises full-year 2025 guidance with 12%-14% organic growth projection
Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ETCompany ParticipantsJon Monson - Senior Vice President,...

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition
Boston Scientific Corporation (NYSE: BSX) on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion . Sales increased 20.9% on a reported bas...

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition
Boston Scientific Corporation BSX on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2211161240-988963093b4c4028b952299234eed592.jpg)
Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire
Shares of Boston Scientific rose sharply Wednesday after the firm posted better-than-expected quarterly results.